Posted On: 12/14/2016 4:33:54 PM
Post# of 1460
10-K is out. They flatly state: "In Septermber 2016, the Company presented positive preclinical data for ANAVEX 2-73 in Parkinson's disease, which demonstrated significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints."
They also talk about how they intend to try to partner up.
They also talk about how they intend to try to partner up.
(1)
(0)
